Subscribe to RSS
DOI: 10.1055/s-2008-1027615
© Georg Thieme Verlag KG Stuttgart · New York
Wundheilungsmodulation nach filtrierenden Glaukomoperationen: Was kommt nach TGF-β?
Beyond TGF-β: Wound Healing Modulation in Filtering Glaucoma SurgeryPublication History
Eingegangen: 1.4.2008
Angenommen: 12.6.2008
Publication Date:
27 January 2009 (online)

Zusammenfassung
Die Vernarbung des operativ geschaffenen Kammerwasserabflusswegs ist das Hauptproblem der filtrierenden Glaukomchirurgie. Zytostatika können die Vernarbung hemmen, doch schränken unerwünschte Wirkungen ihren Einsatz ein. In dieser Übersicht werden Mechanismen und Besonderheiten der Wundheilung nach filtrierenden Glaukomoperationen erörtert und neuere Entwicklungen im Bereich der Wundheilungsmodulation vorgestellt. Der Wachstumsfaktor TGF-β spielt eine zentrale Rolle in der Wundheilung und Narbenbildung, weshalb ein Abfangen von TGF-β und die spezifische Blockade nachgeschalteter intrazellulärer Signale eine verbesserte Wundheilungsmodulation ermöglichen können. Zahlreiche neue Substanzklassen befinden sich in der präklinischen Erprobung und begründen die Hoffnung auf verbesserte Behandlungsmethoden durch eine erweiterte postoperative Kombinationstherapie.
Abstract
Conjunctival scarring remains the major problem in filtering glaucoma surgery. Antimetabolites afford a reduction of scar formation, but considerable side effects limit their application. Here, we review the mechanisms and peculiarities of wound healing following glaucoma surgery and report on new developments in the field of wound healing modulation. The growth factor TGF-β has a central role in wound healing and scarring. Therefore, novel concepts of wound healing modulation comprise scavenging of TGF-β and specific inhibition of disinct downstream intracellular signalling pathways. Several compounds have entered preclinical evaluation and offer new potential to modulate scarring in future combination therapies.
Schlüsselwörter
Glaukom - Wundheilung - TGF-beta
Key words
glaucoma - wound healing - TGF-beta
Literatur
- 1
The Advanced Glaucoma Intervention Study (AGIS) .
7. The relationship between control of intraocular pressure and visual field deterioration.The
AGIS Investigators.
Am J Ophthalmol.
2000;
130 (4)
429-440
MissingFormLabel
- 2
Batterbury M, Wishart P K.
Is high initial aqueous outflow of benefit in trabeculectomy?.
Eye.
1993;
7 (Pt 1)
109-112
MissingFormLabel
- 3
Baudouin C. et al .
Efficacy of indomethacin 0.1 % and fluorometholone 0.1 % on conjunctival inflammation
following chronic application of antiglaucomatous drugs.
Graefes Arch Clin Exp Ophthalmol.
2002;
240 (11)
929-935
MissingFormLabel
- 4
Broadway D C. et al .
Reversal of topical antiglaucoma medication effects on the conjunctiva.
Arch Ophthalmol.
1996;
114 (3)
262-267
MissingFormLabel
- 5
Chang L. et al .
The role of the immune system in conjunctival wound healing after glaucoma surgery.
Surv Ophthalmol.
2000;
45 (1)
49-68
MissingFormLabel
- 6
Chen H S. et al .
Control of filtering bleb structure through tissue bioengineering: An animal model.
Invest Ophthalmol Vis Sci.
2006;
47 (12)
5310-4
MissingFormLabel
- 7
Chicurel M E, Chen C S, Ingber D E.
Cellular control lies in the balance of forces.
Curr Opin Cell Biol.
1998;
10 (2)
232-239
MissingFormLabel
- 8
Cordeiro M F.
Beyond Mitomycin: TGF-beta and wound healing.
Prog Retin Eye Res.
2002;
21 (1)
75-89
MissingFormLabel
- 9
Cordeiro M F, Gay J A, Khaw P T.
Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring
agent.
Invest Ophthalmol Vis Sci.
1999;
40 (10)
2225-2234
MissingFormLabel
- 10
Cordeiro M F. et al .
Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve
surgical outcome.
Gene Ther.
2003;
10 (1)
59-71
MissingFormLabel
- 11
Eibl K H. et al .
Alkylphosphocholines: a new therapeutic option in glaucoma filtration surgery.
Invest Ophthalmol Vis Sci.
2004;
45 (8)
2619-2624
MissingFormLabel
- 12
Eming S A. et al .
Accelerated wound closure in mice deficient for interleukin-10.
Am J Pathol.
2007;
170 (1)
188-202
MissingFormLabel
- 13
Ferguson M W, O’Kane S.
Scar-free healing: from embryonic mechanisms to adult therapeutic intervention.
Philos Trans R Soc Lond B Biol Sci.
2004;
359 (1445)
839-850
MissingFormLabel
- 14
Gabbiani G.
The myofibroblast in wound healing and fibrocontractive diseases.
J Pathol.
2003;
200 (4)
500-503
MissingFormLabel
- 15
Grehn F.
Chirurgie des primären Offenwinkelglaukoms.
Klin Monatsbl Augenheilkd.
2008;
225 (1)
30-38
MissingFormLabel
- 16
Grehn F. et al .
Factors affecting the outcome of trabeculectomy: an analysis based on combined data
from two phase III studies of an antibody to transforming growth factor beta2, CAT-152.
Ophthalmology.
2007;
114 (10)
1831-1838
MissingFormLabel
- 17
Grisanti S. et al .
Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot
study.
Invest Ophthalmol Vis Sci.
2005;
46 (1)
191-196
MissingFormLabel
- 18
Honjo M. et al .
Potential role of Rho-associated protein kinase inhibitor Y-27 632 in glaucoma filtration
surgery.
Invest Ophthalmol Vis Sci.
2007;
48 (12)
5549-5557
MissingFormLabel
- 19
Jendrossek V. et al .
Intracellular mediators of erucylphosphocholine-induced apoptosis.
Oncogene.
2003;
22 (17)
2621-2631
MissingFormLabel
- 20
Khaw P. et al .
A phase III study of subconjunctival human anti-transforming growth factor beta(2)
monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy.
Ophthalmology.
2007;
114 (10)
1822-1830
MissingFormLabel
- 21
Klink T. et al .
Nachsorge nach filtrierenden Glaukomoperationen.
Ophthalmologe.
2006;
103 (9)
815-823
MissingFormLabel
- 22
Klink T, Schrey S, Elsesser U. et al .
Interobserver variability of the Wuerzburg bleb classification score.
Ophthalmologica.
2008;
222
im Druck
MissingFormLabel
- 23
Kumar S, Boehm J, Lee J C.
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory
diseases.
Nat Rev Drug Discov.
2003;
2 (9)
717-726
MissingFormLabel
- 24
Lee J C. et al .
p38 mitogen-activated protein kinase inhibitors – mechanisms and therapeutic potentials.
Pharmacol Ther.
1999;
82 (2 – 3)
389-397
MissingFormLabel
- 25
Marquardt D, Lieb W E, Grehn F.
Intensified postoperative care versus conventional follow-up: a retrospective long-term
analysis of 177 trabeculectomies.
Graefes Arch Clin Exp Ophthalmol.
2004;
242 (2)
106-113
MissingFormLabel
- 26
Martin P. et al .
Wound healing in the PU.1 null mouse – tissue repair is not dependent on inflammatory
cells.
Curr Biol.
2003;
13 (13)
1122-1128
MissingFormLabel
- 27
Mead A L. et al .
Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in
glaucoma surgery.
Invest Ophthalmol Vis Sci.
2003;
44 (8)
3394-3401
MissingFormLabel
- 28
Meyer-ter-Vehn T. et al .
P38 inhibitors prevent TGF-b-induced myofibroblast transdifferentiation in human tenon
fibroblasts.
Invest Ophthalmol Vis Sci.
2006;
47
1500-1509
MissingFormLabel
- 29
Meyer-ter-Vehn T, Grehn F, Schlunck G.
Localization of TGF-beta type II receptor and ED-A fibronectin in normal conjunctiva
and feiled filtering blebs.
Mol Vis.
2008;
14
136-141
MissingFormLabel
- 30
Meyer-ter-Vehn T. et al .
Contractility as a prerequisite for TGF-beta-induced myofibroblast transdifferentiation
in human tenon fibroblasts.
Invest Ophthalmol Vis Sci.
2006;
47 (11)
4895-4904
MissingFormLabel
- 31
Mietz H, Jacobi P C, Krieglstein G K.
Intraoperative episcleral versus postoperative topical application of mitomycin-C
for trabeculectomies.
Ophthalmology.
2002;
109 (7)
1343-1349
MissingFormLabel
- 32
Mietz H, Krieglstein G K.
Postoperative application of mitomycin c improves the complete success rate of primary
trabeculectomy: a prospective, randomized trial.
Graefes Arch Clin Exp Ophthalmol.
2006;
244 (11)
1429-1436
MissingFormLabel
- 33
Ng C P, Hinz B, Swartz M A.
Interstitial fluid flow induces myofibroblast differentiation and collagen alignment
in vitro.
J Cell Sci.
2005;
118 (Pt 20)
4731-4739
MissingFormLabel
- 34
Pasquale L R. et al .
Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment
of the human eye.
Invest Ophthalmol Vis Sci.
1993;
34 (1)
23-30
MissingFormLabel
- 35
Peters T. et al .
Wound-healing defect of CD 18(–/–) mice due to a decrease in TGF-beta1 and myofibroblast
differentiation.
Embo J.
2005;
24 (19)
3400-3410
MissingFormLabel
- 36
Picht G, Grehn F.
Development of the filtering bleb after trabeculectomy. Classification, histopathology,
wound healing process.
Ophthalmologe.
1998;
95 (5)
W380-W387
MissingFormLabel
- 37
Picht G. et al .
Transforming growth factor beta 2 levels in the aqueous humor in different types of
glaucoma and the relation to filtering bleb development.
Graefes Arch Clin Exp Ophthalmol.
2001;
239 (3)
199-207
MissingFormLabel
- 38
Schenk S, Quaranta V.
Tales from the crypt[ic] sites of the extracellular matrix.
Trends Cell Biol.
2003;
13 (7)
366-375
MissingFormLabel
- 39
Serini G. et al .
The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by
transforming growth factor-beta1.
J Cell Biol.
1998;
142 (3)
873-881
MissingFormLabel
- 40
Shah M, Foreman D M, Ferguson M W.
Control of scarring in adult wounds by neutralising antibody to transforming growth
factor beta.
Lancet.
1992;
339 (8787)
213-214
MissingFormLabel
- 41
Shah M, Foreman D M, Ferguson M W.
Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to
cutaneous rat wounds reduces scarring.
J Cell Sci.
1995;
108 (Pt 3)
985-1002
MissingFormLabel
- 42
Shaunak S. et al .
Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation.
Nat Biotechnol.
2004;
22 (8)
977-984
MissingFormLabel
- 43
Siriwardena D. et al .
Human antitransforming growth factor beta(2) monoclonal antibody – a new modulator
of wound healing in trabeculectomy: a randomized placebo controlled clinical study.
Ophthalmology.
2002;
109 (3)
427-431
MissingFormLabel
- 44
Tomasek J J. et al .
Myofibroblasts and mechano-regulation of connective tissue remodelling.
Nat Rev Mol Cell Biol.
2002;
3 (5)
349-363
MissingFormLabel
- 45
Tripathi R C. et al .
Trabecular cells of the eye express messenger RNA for transforming growth factor-beta
1 and secrete this cytokine.
Invest Ophthalmol Vis Sci.
1993;
34 (8)
2562-2569
MissingFormLabel
- 46
Tripathi R C. et al .
Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2.
Exp Eye Res.
1994;
59 (6)
723-727
MissingFormLabel
- 47
Tura A. et al .
The Rho-kinase inhibitor H-1152P suppresses the wound-healing activities of human
Tenon’s capsule fibroblasts in vitro.
Invest Ophthalmol Vis Sci.
2007;
48 (5)
2152-2161
MissingFormLabel
- 48
Wong T T, Mead A L, Khaw P T.
Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration
surgery.
Invest Ophthalmol Vis Sci.
2005;
46 (6)
2018-2022
MissingFormLabel
- 49
Wong T T. et al .
Matrix metalloproteinases in disease and repair processes in the anterior segment.
Surv Ophthalmol.
2002;
47 (3)
239-256
MissingFormLabel
- 50
Yamanaka O. et al .
Inhibition of p38 MAP kinase suppresses fibrogenic reaction in conjunctiva in mice.
Mol Vis.
2007;
13
1730-1739
MissingFormLabel
Dr. Günther Schlunck
Augenklinik und Poliklinik Universität Würzburg
Josef-Schneider-Str. 11
97080 Würzburg
Phone: ++ 49/9 31/20 12 03 51
Fax: ++ 49/9 31/20 12 04 90
Email: schlunck_g@klinik.uni-wuerzburg.de